Lyme disease vaccine faces questions under RFK Jr.

The future of a Lyme disease vaccine in the United States is once again under scrutiny, this time shaped by the stance of Robert F. Kennedy Jr.. While he has pledged to tackle Lyme disease aggressively, it remains unclear whether vaccination will play a central role in that strategy.

The timing is notable. Pfizer recently announced plans to seek regulatory approval for a new Lyme vaccine—the first potential entrant in more than two decades. Yet its path could prove complicated, not only because of scientific and historical hurdles, but also because of the political climate surrounding vaccines.

A growing disease with limited prevention options

Environmental changes are driving its spread. Warmer temperatures linked to climate change are extending tick activity into new regions. At the same time, suburban development has created ideal conditions for rodents that carry the bacteria.

Although antibiotics can treat most early infections, some patients develop long-term symptoms. This has intensified the search for better prevention strategies, including vaccines.

A troubled history still shapes vaccine skepticism

The U.S. has been here before. In 1998, a Lyme vaccine developed by GlaxoSmithKline reached the market. Known as Lymerix, it showed about 75% effectiveness.

However, its rollout was cautious and its adoption limited. Concerns—later found to be unsupported—linked the vaccine to arthritis. Lawsuits followed, public confidence dropped, and the vaccine was withdrawn by 2002 due to low demand.

That episode continues to influence perceptions today. For many patients and advocacy groups, trust in Lyme vaccines remains fragile.

The new vaccine developed by Pfizer and Valneva builds on earlier approaches but includes improvements. It targets multiple strains of Lyme bacteria and removes components once suspected of triggering side effects.

Clinical results suggest similar effectiveness to the earlier vaccine, with roughly 75% protection after multiple doses. Still, experts warn that a four-dose schedule could limit uptake.

Some advocates also note that the vaccine addresses only Lyme disease—not other infections transmitted by ticks. This raises concerns about a false sense of protection.

RFK Jr.’s stance could shape the outcome

At the center of the debate is Kennedy himself. As head of the US Department of Health and Human Services, he oversees agencies critical to vaccine approval and distribution.

Kennedy has long expressed skepticism toward vaccines and has promoted controversial claims about Lyme disease’s origins. Although he has pledged to support solutions, his focus has leaned more toward diagnostics and treatment rather than prevention through vaccination.

His influence extends beyond policy. Recent changes to vaccine advisory bodies and regulatory leadership have already created uncertainty within the pharmaceutical industry.

An open question for public health

The success of a Lyme disease vaccine will depend on more than scientific results. Public trust, regulatory support, and political leadership will all play decisive roles.

For now, the U.S. faces a growing health threat with limited prevention tools—and an unresolved question: whether vaccination will be part of the answer this time.